$THC

HANEY CECIL D sold (to issuer) $86K of THC

HANEY CECIL D sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · HANEY CECIL D
Published May 27, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure updates insider ownership but does not include any operational, regulatory, or financial developments for Tenet Healthcare.

02

Market read

Traders may briefly reassess sentiment around THC due to insider selling, but the event lacks fundamental catalysts.

03

What to watch

No 10b5-1 plan is cited, but the transaction code D (sale to issuer) can still be non-informational; watch for subsequent insider buys/sales or larger institutional changes.

Relevance 6/10Timing: Filing dated 2026-05-26 for a transaction on 2026-05-22; impact, if any, is most relevant around the filing window.

Background

SEC Form 4 discloses insider transactions; code D indicates sale to the issuer (e.g., buyback participation).

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director Haney Cecil D sold 493 shares to the issuer for about $85.7K at $173.78/share, per SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely small and short-lived unless follow-on filings show broader selling.

Evidence & confidence

Single director transaction size is small versus typical market moves, and the filing provides no new company-specific operating or financial information.

Market effects

No clear read-through to healthcare sector fundamentals from a single director Form 4 sale.

None indicated.

None indicated.

Counterpoint

Because the sale is to the issuer (often tied to buyback/plan mechanics), it may reflect routine liquidity or corporate action rather than bearish expectations.

Key entities

  • Tenet Healthcare Corp

    Company whose director insider transaction was reported on SEC Form 4.

  • Haney Cecil D

    Tenet Healthcare director who sold 493 shares to the issuer on 2026-05-22.

Related articles

$HCAMed

Uninsured patients rise sharply, hospitals report, citing Obamacare cuts | Chattanooga Times Free Press

More and more uninsured patients are showing up in hospital emergency rooms and clinics, having lost their coverage under the Affordable Care Act. Executives running some of the biggest hospital systems, including large for-profit chains spanning many states, expressed concern over the unexpectedly sharp rise in uninsured patients and the costs associated with treating them.

$THCMedAI 8/10

Tenet raises 2026 outlook after weathering ACA headwinds

Tenet Healthcare raised 2026 guidance after Q2 headwinds on Affordable Care Act exchanges. The company now expects adjusted EBITDA of $4.8B to $5.0B, up from $4.5B to $4.8B. Q2 net income rose to $826M on $5.6B revenue, though ACA revenue fell $65M as ACA admissions declined.

$THCHighAI 9/10

Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook

Tenet Healthcare (THC) reported Q2 2026 adjusted EPS of $6.12, 50% above the Zacks Consensus, with net operating revenues up 6.8% to $5.63B. Adjusted net income rose 39.3% to $514M. The company raised 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, and authorized a $2B share repurchase increase.

$THCMedAI 8/10

Why Tenet Healthcare Stock Is Soaring Today

Tenet Healthcare (THC) shares rose after the company reported fiscal Q2 results and raised 2026 guidance. For the quarter ended in June, revenue was $5.63B and adjusted EPS was $6.12, both above year-ago figures and analyst estimates ($5.43B revenue, $4.26 EPS). 2026 revenue guidance increased to $21.9B-$22.5B and adjusted EBITDA to $4.83B-$5.03B.